‘Too good to be true' now passes as a decisive scientific criteria
In the early days of the COVID pandemic a research team led by Brazilian physician Flavio Cadegiani has discovered that an experimental prostate cancer drug named proxalutamide reduced all-cause mortality in hospitalized COVID patients by 77%. The team's findings are published as pre-print and are still under that status even though they were published on 22 June 2021. Isn't it strange that in the time of a supposedly deadly pandemic a potentially highly successful treatment wouldn't be carefully scrutinized and either confirmed as effective or proven ineffective when there is such a promising potential of it actually being a highly effective treatment option? Why would an article like this not be peer reviewed and published or rejected in such a long period, given the situation we are told we are in?
What did happen as a response to this article is a rebuttal in Scinece. The article literally casts skepticism on these findings as being "too good to be true". No kidding. No issues with the methodology, no faults stated - just "too good to be true".
Meanwhile, we still have officials fawning over novel mRNA COVID vaccines as being "safe and effective". Even now that we know that these vaccines neither stop the transmission of the virus, nor provide much protection against the symptoms - at least a few months after you receive the jab.
One is left wondering what's behind this disparity in assessment standards.
References
‘Too good to be true': Doubts swirl around trial that saw 77% reduction in COVID-19 mortality
Robert F. Service, Science, 7 July 2021
Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
Flávio Adsuara Cadegiani, Daniel do Nascimento Fonseca, John McCoy, Ricardo Ariel Zimerman, Fatima Nadeem Mirza, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Brenda Gomes de Almeida, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Gabriel de Souza Ferreira, Flavio Renan Paula da Costa Alcântara, Ângelo Macedo Ribeiro, Felipe Oliveira de Almeida, Adailson Antonio de Souza Silva, Suzyane Serfaty do Rosario, Raysa Wanzeller de Souza Paulain, Alessandra Reis, Marissa Li, Claudia Elizabeth Thompson, Gerard J. Nau, Carlos Gustavo Wambier, Andy Goren, BMJ, 22 June 2021
US COVID vaccines: their power fleeting, their usefulness limited
@borepstein, 7 November 2021
Social media links
Website
Support
They say that those vaccines prevent us from death or help our immune system to have Covid with light symptoms.
Both need to be proven purely.
perhaps officials and doctors were afraid to touch this out of fear of having their careers and reputations tarnished by the elites just like they did with several other therapeutics.
I look at this the same way I look at most of the wars the USA has been involved in: The objective was never to win, just to sustain the situation as long as possible.